286-300 of 305
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CEUtilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CETROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Benjamin Levy, MD
Rebecca Heist, MD, MPH
Peter Bela Illei, MD
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
CME/CEImproved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
Ayse Tuba Kendi, MD
A. Oliver Sartor, MD
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
Jaffer Ajani, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
Sara A. Hurvitz, MD, FACP
- advertisement
Sara A. Hurvitz, MD, FACP
Sara A. Hurvitz, MD, FACP
Justin Gainor, MD
Justin Gainor, MD
Justin Gainor, MD
Jaffer Ajani, MD
- advertisement
Gopa Iyer, MD
Gopa Iyer, MD
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
CME/CEA Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
Jennifer Caudle, DO, FACOFP
Mikkael A. Sekeres, MD, MS
Sara M. Tinsley, PhD, ARNP, AOCNP
